Publications by authors named "Susan Ramadan"

Claim this Profile
M
Multicentre evaluation of deep learning CT autosegmentation of the head and neck region for radiotherapy.
Eric Pei Ping Pang, Hong Qi Tan, Fuqiang Wang, Jarkko Niemelä, Gregory Bolard, Susan Ramadan

NPJ Digit Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial.
Matthew Stephen Block, James Hugo Armstrong Clubb, Johanna Mäenpää, Santeri Pakola, Dafne Carolina Alves Quixabeira, Susan Ramadan

Nat Commun· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.
Kalle E Mattila, Siru Mäkelä, Soili Kytölä, Emma Andersson, Pia Vihinen, Susan Ramadan

Acta Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma.
Kalle E Mattila, Pia Vihinen, Susan Ramadan, Tanja Skyttä, Leena Tiainen

Acta Oncol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Ivan Jambor, Anna Kuisma, Susan Ramadan, Riikka Huovinen, Minna Sandell

Acta Oncol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating levels of VEGFR-1 and VEGFR-2 in patients with metastatic melanoma treated with chemoimmunotherapy alone or combined with bevacizumab.
Pia P Vihinen, Susan Ramadan, Meri-Sisko Vuoristo, Micaela Hernberg, Kristiina Tyynelä-Korhonen

Melanoma Res· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis